Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors-Reference-Cited by-同舟云学术

Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors

Published:2021-05-07 Issue:9 Volume:56 Page:2231-2240
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Shiratori Souichi^ORCID,Sugita Junichi,Fuji Shigeo,Aoki Jun^ORCID,Sawa Masashi,Ozawa Yukiyasu,Hashimoto Daigo,Matsuoka Ken-ichi^ORCID,Imada Kazunori,Doki Noriko,Ashida Takashi,Ueda Yasunori,Tanaka Masatsugu,Sawayama Yasushi,Ichinohe Tatsuo^ORCID,Terakura Seitaro^ORCID,Morishima Satoko^ORCID,Atsuta Yoshiko^ORCID,Fukuda Takahiro,Teshima Takanori^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01314-w.pdf

Reference49 articles.

1. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, et al. Long-term outcome and late effects in patients transplantedwith mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010;11:331–8.

2. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl J Med. 2012;367:1487–96.

3. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.